Особенности применения эртапенема у пациентов в критических состояниях
Аннотация
В статье обсуждаются особенности применения эртапенема, беталактамного антибиотика, относящегося к группе карбапенемов.
Об авторе
В. Б. Белобородов
Российская медицинская академия последипломного образования, Москва
Россия
Россия
Список литературы
1. Craig W.A. Pharmacodynamics of antimicrobials: general concepts and applications. In: Nightingale C., Marakawa T., Ambrose P.G., eds. Antimicrobial Pharmacodynamics in Theory and Clinical Practice. New York: Marcel-Dekker, 2002; 1-22.
2. Liu P., Derendorf H. Antimicrobial tissue concentrations. Infect Dis Clin North Am 2003; 17: 599-613.
3. Muller M., dela Pena A., Derendorf H. Issues in pharmacokinetics and pharmacodynamics of anti-infective agents: distribution in tissue. Antimicrob Agents Chemother 2004; 48: 1441-1453.
4. Burke J.P. Infections control - а problem for patient safety. N Engl J Med 2003; 348: 651-656.
5. Fung H.B., Chang J.Y., Kuczynski S. A practical guide to the treatment of complicated skin and soft tissue infections. Drugs 2003; 63: 1459-1480.
6. Giurini J.M., Lyons T.E. Diabetic foot complications: diagnosis and management. Int J Low Extrem Wounds 2005; 4: 171-182.
7. Kunin C.M., Craig W.A., Kornguth M. et al. Influence of binding on the pharmacologic activity of antibiotics. Ann NY Acad Sci 1973; 226: 214-224.
8. Merrikin D.J., Briant J., Rolinson G.N. Effect of protein binding on antibiotic activity in vivo. J Antimicrob Chemother 1993; 11: 233-238.
9. Fuchs P.C., Barry A.L., Brown S.D. In vitro activities of ertapenem (MK-0826) against clinical bacterial isolates from 11 North American medical centers. Antimicrobial Agents Chemotherapy 2001; 45, 1915-1918.
10. Livermore D.M., Carter M.W., Bagel S. et al. In vitro activities of ertapenem (MK-0826) against recent clinical bacteria collected in Europe and Australia. Antimicrobial Agents and Chemotherapy 2001; 45, 1860-1867.
11. Roy S., Higareda I., Angel-Muller E., Ismail M., et al. Results of a phase III randomized, doubleblind study of ertapenem vs piperacillin-tazobactam for acute pelvic infection in women. Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL, 2001. Abstract L-888, p. 456.
12. Pelak B.A., Citron D.M., Motyll M. et al. Comparative in vitro activities of ertapenem against bacterial pathogens from patients with acute pelvic infection. Journal of Antimicrob Chemother 2002; 50, 735-741.
13. Barker K.F. Antibiotic resistance: a current perspective. Br J Clin Pharmacol 1999; 48: 109-124.
14. Cunha B.A. Ertapenem. A review of its microbiologic, pharmacokinetic and clinical aspects. Drugs Today 2002; 38: 195-213.
15. Majumdar A., Musson D.G., Birk K.L. et al. Pharmacokinetics of ertapenem in healthy young volunteers. Antimicrob Agents Chemother 2002; 46: 3506-3511.
16. Laethem T., De Lepeleire I., McCrea J. et al. Tissue penetration by ertapenem, a parenteral carbapenem administered once daily, in suction-induced skin blister fluid in healthy young volunteers. Antimicrob Agents Chemother. 2003; 47: 1439-1442.
17. Burkhardt O., Majcher-Peszynska J., Borner K. et al. Penetration of ertapenem into different pulmonary compartments of patients undergoing lung surgery. J Clin Pharmacol 2005; 45: 659-665.
18. Burkhardt O., Kumar , Katterwe D. et al. Ertapenem in critically ill patients with early-onset ventilator-associated pneumonia: pharmacokinetics with special consideration of free-drug concentration. Journal of Antimicrobial Chemotherapy 2007; 59: 277-284.
19. Nix D.E., Majumdar A.K., DiNubile M.J. Pharmacokinetics and pharmacodynamics of ertapenem: an overview for clinicians. J Antimicrob Chemother 2004; 53 Suppl 2: ii23-28.
20. Brunner M., Hollenstein U., Delacher S. et al. Distribution and antimicrobial activity of ciprofloxacin in human soft tissues. Antimicrob Agents Chemother 1999; 43: 1307-1309.
21. Schuck E.L., Derendorf H. Pharmacokinetic/pharmacodynamic evaluation of anti-infective agents. Expert Rev Anti Infect Ther 2005; 3: 361-373.
22. Mouton J.W., Touzw D.J., Horrevorts A.M. et al. Comparative pharmacokinetics of the carbapenems: clinical implications. Clin Pharmacokinet 2000; 39: 185-201.
23. Livermore D.M., Oakton K.J., Carter M.W. et al. Activity of ertapenem (MK-0826) versus Enterobacteriaceae with potent β-lactamases. Antimicrob Agents Chemother 2001; 45: 2831-29307.
24. Burkhardt O., Brunner M., Schmidt S. et al. Penetration of ertapenem into skeletal muscle and subcutaneous adipose tissue in healthy volunteers measured by in vivo microdialysis. Journal of Antimicrobial Chemotherapy 2006; 58: 632-636.
25. Turnidge J.D. The pharmacodynamics of betalactams. Clin Infect Dis 1998; 27: 10-22.
26. Friedland I., Mixson L.A., Majumdar A. et al. In vitro activity of ertapenem against common clinical isolates in relation to human pharmacokinetics. J Chemother 2002; 14: 483-491.
27. Craig W.A. Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin Infect Dis 1998; 26: 1-10.
28. Solomkin J.S., Yellin A.E., Rotstein O.D. et al. Ertapenem versus piperacillin/tazobactam in the treatment of complicated intraabdominal infections: results of a double blind, randomized comparative phase III trial. Ann Surg 2003; 237: 235-245.
29. Yellin A.E., Hassett J.M., Fernandez A. et al. Ertapenem monotherapy versus combined therapy with ceftriaxone plus metronidazole for treatment of complicated intraabdominal infections in adults. Int J Antimicrob Agents 2002; 20: 165-167.
30. Musson D.G., Majumdar A., Holland S. et al. Pharmacokinetics of total and unbound ertapenem in healthy elderly subjects. Antimicrob Agents Chemother 2004; 48: 521-524.
31. Pletz M.W.R., Rau M., Bulitta J. et al. Ertapenem pharmacokinetics and impact on intestinal microflora, in comparison to those of ceftriaxone, after multiple dosing in male and female volunteers. Antimicrob Agents Chemother 2004; 48: 3765-72.15 16
32. Power B.M., Forbes A.M., Van Heerden P.V. et al. Pharmacokinetics of drugs in critically ill patients. Clin Pharmacokinet 1998; 34: 25-56.
33. Pea F., Viale P., Furlanut M. Antimicrobial therapy in critically ill patients: a review of pathophysiological conditions responsible for altered disposition and pharmacokinetic variability. Clin Pharmacokinet 2005; 44: 1009-1034.
34. Joynt G.M., Lipman J., Gomersall C.D. et al. The pharmacokinetics of once-daily dosing of ceftriaxone in critically ill patients. J Antimicrob Chemother 2001; 47: 421-429
35. Wexler H.M. In vitro activity of ertapenem: review of recent studies. J Antimicrob Chemother 2004; 53 Suppl. 2: 11-21.
36. Shah P.M., Isaacs R.D. Ertapenem, the first of a new group of car-bapenems. J Antimicrob Chemother 2003; 52: 538-542.
37. Livermore D.M., Sefton A.M., Scott G.M. Properties and potential of ertapenem. J Antimicrob Chemother 2003; 52: 331-344.
38. Chen M., Nafziger A.N., Drusano G.L., Ma L., Bertino J.S. Jr. Comparative pharmacokinetics and pharmacodynamic target attainment of ertapenem in normal-weight, obese, and extremely obese adults. Antimicrob Agents Chemother 2006; 50: 1222-1227.
Рецензия
Для цитирования:
Белобородов В.Б. Особенности применения эртапенема у пациентов в критических состояниях. Антибиотики и Химиотерапия. 2011;56(3-4):10-16.
For citation:
Beloborodov V.B. Characteristics of Ertapenem Use in Critical State Patients. Antibiot Khimioter = Antibiotics and Chemotherapy. 2011;56(3-4):10-16. (In Russ.)
Просмотров:
315
Послать статью по эл. почте 